NEWS RELEASES
Search all of our news releases here.
American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference
ROCKVILLE, MD, UNITED STATES, January 7, 2019 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 7-10 in San Francisco, California. American Gene Technologies invitation to attend the…
Read More
American Gene Technologies Granted FDA Orphan Drug Designation For Phenylketonuria
ROCKVILLE, MD, UNITED STATES, October 18, 2018 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment…
Read More
American Gene Technologies to Present at 2018 Cell and Gene Meeting On The Mesa
ROCKVILLE, MD, UNITED STATES, September 26, 2018 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, California.…
Read More
Immunotherapy CEO Jeff Galvin Joins The Board of Directors of the Cancer Support Community
ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ — Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC).…
Read More
American Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs
ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors…
Read More
American Gene Technologies CEO Jeff Galvin Joins Maryland Tech Council Board of Directors
ROCKVILLE, MD, UNITED STATES, August 20, 2018 /EINPresswire.com/ — American Gene Technologies International Inc. (AGT)’s CEO and founder Jeff Galvin has been appointed to the Board of Directors of the Maryland Tech Council, the largest Maryland technology trade association, representing over 600 companies across the…
Read More
American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention
ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) – American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as…
Read More
American Gene Technologies Gains Additional Immuno-Oncology Patent
Novel approach to activating gamma delta T cells shows promise in animal studies — demonstrating efficacy in multiple epithelial solid tumors and metastases ROCKVILLE, Md., March 19, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced…
Read More
American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure
Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 – American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes…
Read More
American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer through Activation of Gamma Delta T Cells
Patent encompasses AGT’s advanced gene and cell therapy strategy for oncology ROCKVILLE, MD, December 12, 2017 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced the issuance of U.S. Patent No: 9,834,790 dated December 5, 2017, covering methods…
Read MoreSubscribe to News Releases and News Updates
Subscribe to our news release and published article updates to be notified when we release new content!
Follow AGT on Social Media
AGT on Facebook
